These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28745507)

  • 1. Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide.
    Liu J; Sun B; Zhao X; Xing J; Gao Y; Chang W; Ji J; Zheng H; Cui C; Ji A; Lou H
    J Med Chem; 2017 Aug; 60(16):7166-7185. PubMed ID: 28745507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.
    Chelliah MV; Chackalamannil S; Xia Y; Eagen K; Clasby MC; Gao X; Greenlee W; Ahn HS; Agans-Fantuzzi J; Boykow G; Hsieh Y; Bryant M; Palamanda J; Chan TM; Hesk D; Chintala M
    J Med Chem; 2007 Oct; 50(21):5147-60. PubMed ID: 17854166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
    Chackalamannil S; Wang Y; Greenlee WJ; Hu Z; Xia Y; Ahn HS; Boykow G; Hsieh Y; Palamanda J; Agans-Fantuzzi J; Kurowski S; Graziano M; Chintala M
    J Med Chem; 2008 Jun; 51(11):3061-4. PubMed ID: 18447380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.
    Chackalamannil S; Xia Y; Greenlee WJ; Clasby M; Doller D; Tsai H; Asberom T; Czarniecki M; Ahn HS; Boykow G; Foster C; Agans-Fantuzzi J; Bryant M; Lau J; Chintala M
    J Med Chem; 2005 Sep; 48(19):5884-7. PubMed ID: 16161991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of nor-seco himbacine analogs as thrombin receptor antagonists.
    Chelliah MV; Chackalamannil S; Xia Y; Eagen K; Greenlee WJ; Ahn HS; Agans-Fantuzzi J; Boykow G; Hsieh Y; Bryant M; Chan TM; Chintala M
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2544-9. PubMed ID: 22405832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.
    Perez M; Lamothe M; Maraval C; Mirabel E; Loubat C; Planty B; Horn C; Michaux J; Marrot S; Letienne R; Pignier C; Bocquet A; Nadal-Wollbold F; Cussac D; de Vries L; Le Grand B
    J Med Chem; 2009 Oct; 52(19):5826-36. PubMed ID: 19791800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.
    Dumas M; Nadal-Wollbold F; Gaussem P; Perez M; Mirault T; Létienne R; Bourbon T; Grelac F; Le Grand B; Bachelot-Loza C
    Br J Pharmacol; 2012 Mar; 165(6):1827-1835. PubMed ID: 21913899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
    Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
    Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism-based identification of a potent thrombin receptor antagonist.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee W; Kao G; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Smith-Torhan A; Alton K; Bryant M; Hsieh Y; Lau J; Palamanda J
    J Med Chem; 2007 Jan; 50(1):129-38. PubMed ID: 17201416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
    Lee S
    Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time.
    Nadal-Wollbold F; Bocquet A; Bourbon T; Létienne R; Le Grand B
    Eur J Pharmacol; 2010 Oct; 644(1-3):188-94. PubMed ID: 20655904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent.
    French SL; Arthur JF; Tran HA; Hamilton JR
    Blood Rev; 2015 May; 29(3):179-89. PubMed ID: 25467961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
    Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
    Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide with etoricoxib after oral administration in rats.
    Balap A; Atre B; Lohidasan S; Sinnathambi A; Mahadik K
    J Ethnopharmacol; 2016 May; 183():9-17. PubMed ID: 26593212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
    Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
    Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
    Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
    Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
    Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects.
    Chackalamannil S
    J Med Chem; 2006 Sep; 49(18):5389-403. PubMed ID: 16942011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.